1
|
Antinucci M, Comas D, Calafell F. Population history modulates the fitness effects of Copy Number Variation in the Roma. Hum Genet 2023; 142:1327-1343. [PMID: 37311904 PMCID: PMC10449987 DOI: 10.1007/s00439-023-02579-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Accepted: 06/02/2023] [Indexed: 06/15/2023]
Abstract
We provide the first whole genome Copy Number Variant (CNV) study addressing Roma, along with reference populations from South Asia, the Middle East and Europe. Using CNV calling software for short-read sequence data, we identified 3171 deletions and 489 duplications. Taking into account the known population history of the Roma, as inferred from whole genome nucleotide variation, we could discern how this history has shaped CNV variation. As expected, patterns of deletion variation, but not duplication, in the Roma followed those obtained from single nucleotide polymorphisms (SNPs). Reduced effective population size resulting in slightly relaxed natural selection may explain our observation of an increase in intronic (but not exonic) deletions within Loss of Function (LoF)-intolerant genes. Over-representation analysis for LoF-intolerant gene sets hosting intronic deletions highlights a substantial accumulation of shared biological processes in Roma, intriguingly related to signaling, nervous system and development features, which may be related to the known profile of private disease in the population. Finally, we show the link between deletions and known trait-related SNPs reported in the genome-wide association study (GWAS) catalog, which exhibited even frequency distributions among the studied populations. This suggests that, in general human populations, the strong association between deletions and SNPs associated to biomedical conditions and traits could be widespread across continental populations, reflecting a common background of potentially disease/trait-related CNVs.
Collapse
Affiliation(s)
- Marco Antinucci
- Institute of Evolutionary Biology (UPF-CSIC), Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain
| | - David Comas
- Institute of Evolutionary Biology (UPF-CSIC), Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain
| | - Francesc Calafell
- Institute of Evolutionary Biology (UPF-CSIC), Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
| |
Collapse
|
2
|
Liu L, Tang M, Pragani R, Whitby FG, Zhang YQ, Balakrishnan B, Fang Y, Karavadhi S, Tao D, LeClair CA, Hall MD, Marugan JJ, Boxer M, Shen M, Hill CP, Lai K, Patnaik S. Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors. J Med Chem 2021; 64:13551-13571. [PMID: 34491744 DOI: 10.1021/acs.jmedchem.1c00945] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Classic galactosemia is a rare disease caused by inherited deficiency of galactose-1 phosphate uridylyltransferase (GALT). Accumulation of galactose-1 phosphate (gal-1P) is thought to be the major cause of the chronic complications associated with this disease, which currently has no treatment. Inhibiting galactokinase (GALK1), the enzyme that generates galactose-1 phosphate, has been proposed as a novel strategy for treating classic galactosemia. Our previous work identified a highly selective unique dihydropyrimidine inhibitor against GALK1. With the determination of a co-crystal structure of this inhibitor with human GALK1, we initiated a structure-based structure-activity relationship (SAR) optimization campaign that yielded novel analogs with potent biochemical inhibition (IC50 < 100 nM). Lead compounds were also able to prevent gal-1P accumulation in patient-derived cells at low micromolar concentrations and have pharmacokinetic properties suitable for evaluation in rodent models of galactosemia.
Collapse
Affiliation(s)
- Li Liu
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Manshu Tang
- Department of Pediatrics, University of Utah, Salt Lake City, Utah 84108-6500, United States
| | - Rajan Pragani
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Frank G Whitby
- Department of Biochemistry, University of Utah School of Medicine, 15 North Medical Drive East, Salt Lake City, Utah 84112, United States
| | - Ya-Qin Zhang
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Bijina Balakrishnan
- Department of Pediatrics, University of Utah, Salt Lake City, Utah 84108-6500, United States
| | - Yuhong Fang
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Surendra Karavadhi
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Dingyin Tao
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Christopher A LeClair
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Matthew D Hall
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Juan J Marugan
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Matthew Boxer
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Min Shen
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Christopher P Hill
- Department of Biochemistry, University of Utah School of Medicine, 15 North Medical Drive East, Salt Lake City, Utah 84112, United States
| | - Kent Lai
- Department of Pediatrics, University of Utah, Salt Lake City, Utah 84108-6500, United States
| | - Samarjit Patnaik
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| |
Collapse
|
3
|
Cordeiro C, Garcia P, Coelho D, Oliva M. Galactokinase deficiency: a treatable cause of bilateral cataracts. BMJ Case Rep 2021; 14:14/6/e242227. [PMID: 34088690 DOI: 10.1136/bcr-2021-242227] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Congenital cataract can be caused by several systemic diseases and differential diagnosis should be done between infections, genetic or metabolic diseases. We present a case of a 12-month-old girl with bilateral nuclear cataracts that was referred for investigation. Since she did not present a family history of congenital cataracts or metabolic diseases, and her physical examination was normal, a systemic evaluation was performed. Biochemical studies disclosed abnormal galactose metabolism signs. The diagnosis of galactokinase (GALK1) deficiency was considered and the study of the GALK1 gene allowed identifying a pathogenic genetic variant and a predictably pathogenic missense mutation, previously not described. Dietary measures were imposed with a good evolution.
Collapse
Affiliation(s)
- Catarina Cordeiro
- Departamento Pediátrico - Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal
| | - Paula Garcia
- Departamento Pediátrico - Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal
| | - Dalila Coelho
- Departamento Pediátrico - Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal
| | - Mónica Oliva
- Departamento Pediátrico - Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal
| |
Collapse
|
4
|
Mavillard F, Servián-Morilla E, Rivas E, Paradas C, Cabrera-Serrano M. Novel ANO5 intronic Roma variant alters splicing causing muscular dystrophy. Clin Genet 2021; 100:106-110. [PMID: 33818761 DOI: 10.1111/cge.13964] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Revised: 03/29/2021] [Accepted: 03/31/2021] [Indexed: 11/29/2022]
Abstract
The pathogenic role of intronic variants is generally difficult to assess, except for those near known splice sites for which aberrant splicing is suspected, although deeper intronic variants can also alter splicing. We have identified a novel (NM_213599.2:c.1180+6T>C) ANO5 variant that causes the exclusion of exon 12. The mutation, identified in a Roma individual, has an estimated carrier rate of 1.68% among the Iberian Roma population, this being the first ANO5 pathogenic variant communicated in this ethnic group. In this study, we have also characterized the ANO5 splice forms expressed in human muscle with the detection of an alternative transcript, in which exons 8 and 9 are spliced out.
Collapse
Affiliation(s)
- Fabiola Mavillard
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.,Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de salud Carlos III, Sevilla, Spain
| | - Emilia Servián-Morilla
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.,Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de salud Carlos III, Sevilla, Spain
| | - Eloy Rivas
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.,Department of Pathology, Hospital U. Virgen del Rocío, Sevilla, Spain
| | - Carmen Paradas
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.,Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de salud Carlos III, Sevilla, Spain.,Department of Neurology, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Consejo Superior de Investigaciones Científicas/Universidad de Sevilla, Sevilla, Spain
| | - Macarena Cabrera-Serrano
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.,Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de salud Carlos III, Sevilla, Spain.,Department of Neurology, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Consejo Superior de Investigaciones Científicas/Universidad de Sevilla, Sevilla, Spain
| |
Collapse
|
5
|
Font-Porterias N, Caro-Consuegra R, Lucas-Sánchez M, Lopez M, Giménez A, Carballo-Mesa A, Bosch E, Calafell F, Quintana-Murci L, Comas D. The Counteracting Effects of Demography on Functional Genomic Variation: The Roma Paradigm. Mol Biol Evol 2021; 38:2804-2817. [PMID: 33713133 PMCID: PMC8233508 DOI: 10.1093/molbev/msab070] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Demographic history plays a major role in shaping the distribution of genomic variation. Yet the interaction between different demographic forces and their effects in the genomes is not fully resolved in human populations. Here, we focus on the Roma population, the largest transnational ethnic minority in Europe. They have a South Asian origin and their demographic history is characterized by recent dispersals, multiple founder events, and extensive gene flow from non-Roma groups. Through the analyses of new high-coverage whole exome sequences and genome-wide array data for 89 Iberian Roma individuals together with forward simulations, we show that founder effects have reduced their genetic diversity and proportion of rare variants, gene flow has counteracted the increase in mutational load, runs of homozygosity show ancestry-specific patterns of accumulation of deleterious homozygotes, and selection signals primarily derive from preadmixture adaptation in the Roma population sources. The present study shows how two demographic forces, bottlenecks and admixture, act in opposite directions and have long-term balancing effects on the Roma genomes. Understanding how demography and gene flow shape the genome of an admixed population provides an opportunity to elucidate how genomic variation is modeled in human populations.
Collapse
Affiliation(s)
- Neus Font-Porterias
- Departament de Ciències Experimentals i de la Salut, Institut de Biologia Evolutiva (UPF-CSIC), Universitat Pompeu Fabra, Barcelona, Spain
| | - Rocio Caro-Consuegra
- Departament de Ciències Experimentals i de la Salut, Institut de Biologia Evolutiva (UPF-CSIC), Universitat Pompeu Fabra, Barcelona, Spain
| | - Marcel Lucas-Sánchez
- Departament de Ciències Experimentals i de la Salut, Institut de Biologia Evolutiva (UPF-CSIC), Universitat Pompeu Fabra, Barcelona, Spain
| | - Marie Lopez
- Human Evolutionary Genetics Unit, Institut Pasteur, UMR2000, CNRS, Paris, France
| | - Aaron Giménez
- Facultat de Sociologia, Universitat Autònoma de Barcelona, Barcelona, Spain
| | | | - Elena Bosch
- Departament de Ciències Experimentals i de la Salut, Institut de Biologia Evolutiva (UPF-CSIC), Universitat Pompeu Fabra, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Reus, Spain
| | - Francesc Calafell
- Departament de Ciències Experimentals i de la Salut, Institut de Biologia Evolutiva (UPF-CSIC), Universitat Pompeu Fabra, Barcelona, Spain
| | - Lluís Quintana-Murci
- Human Evolutionary Genetics Unit, Institut Pasteur, UMR2000, CNRS, Paris, France.,Human Genomics and Evolution, Collège de France, Paris, France
| | - David Comas
- Departament de Ciències Experimentals i de la Salut, Institut de Biologia Evolutiva (UPF-CSIC), Universitat Pompeu Fabra, Barcelona, Spain
| |
Collapse
|
6
|
Dlouhá L, Adámková V, Šedová L, Olišarová V, Hubáček JA, Tóthová V. Five genetic polymorphisms of cytochrome P450 enzymes in the Czech non-Roma and Czech Roma population samples. Drug Metab Pers Ther 2020; 35:/j/dmdi.2020.35.issue-2/dmpt-2020-0103/dmpt-2020-0103.xml. [PMID: 32681777 DOI: 10.1515/dmpt-2020-0103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Accepted: 04/20/2020] [Indexed: 06/11/2023]
Abstract
Objectives Cytochromes P450 play a role in human drugs metabolic pathways and their genes are among the most variable in humans. The aim of this study was to analyze genotype frequencies of five common polymorphisms of cytochromes P450 in Roma/Gypsy and Czech (non-Roma) population samples with Czech origin. Methods Roma/Gypsy (n=302) and Czech subjects (n=298) were genotyped for CYP1A2 (rs762551), CYP2A6 (rs4105144), CYP2B6 (rs3745274) and CYP2D6 (rs3892097; rs1065852) polymorphisms using PCR-RFLP or Taqman assay. Results We found significant allelic/genotype differences between ethnics in three genes. For rs3745274 polymorphism, there was increased frequency of T allele carriers in Roma in comparison with Czech population (53.1 vs. 43.7%; p=0.02). For rs4105144 (CYP2A6) there was higher frequency of T allele carriers in Roma in comparison with Czech population (68.7 vs. 49.8%; p<0.0001). For rs3892097 (CYP2D6) there was more carriers of the A allele between Roma in comparison with Czech population (39.2 vs. 38.2%; p=0.048). Genotype/allelic frequencies of CYP2D6 (rs1065852) and CYP1A2 (rs762551) variants did not significantly differ between the ethnics. Conclusions There were significant differences in allelic/genotype frequencies of some, but not all cytochromes P450 polymorphisms between the Czech Roma/Gypsies and Czech non-Roma subjects.
Collapse
Affiliation(s)
- Lucie Dlouhá
- Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- Department of Anthropology and Human Genetics, Faculty of Science, Charles University, Prague, Czech Republic
| | - Věra Adámková
- Department of Preventive Cardiology for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - Lenka Šedová
- Faculty of Health and Social Sciences, University of South Bohemia, České Budejovice, Czech Republic
| | - Věra Olišarová
- Faculty of Health and Social Sciences, University of South Bohemia, České Budejovice, Czech Republic
| | - Jaroslav A Hubáček
- Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - Valérie Tóthová
- Faculty of Health and Social Sciences, University of South Bohemia, České Budejovice, Czech Republic
| |
Collapse
|
7
|
Dlouhá L, Adámková V, Šedová L, Olišarová V, Hubáček JA, Tóthová V. Five genetic polymorphisms of cytochrome P450 enzymes in the Czech non-Roma and Czech Roma population samples. Drug Metab Pers Ther 2020; 0:/j/dmdi.ahead-of-print/dmdi-2020-0103/dmdi-2020-0103.xml. [PMID: 32609646 DOI: 10.1515/dmdi-2020-0103] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Accepted: 04/20/2020] [Indexed: 01/15/2023]
Abstract
Objectives Cytochromes P450 play a role in human drugs metabolic pathways and their genes are among the most variable in humans. The aim of this study was to analyze genotype frequencies of five common polymorphisms of cytochromes P450 in Roma/Gypsy and Czech (non-Roma) population samples with Czech origin. Methods Roma/Gypsy (n=302) and Czech subjects (n=298) were genotyped for CYP1A2 (rs762551), CYP2A6 (rs4105144), CYP2B6 (rs3745274) and CYP2D6 (rs3892097; rs1065852) polymorphisms using PCR-RFLP or Taqman assay. Results We found significant allelic/genotype differences between ethnics in three genes. For rs3745274 polymorphism, there was increased frequency of T allele carriers in Roma in comparison with Czech population (53.1 vs. 43.7%; p=0.02). For rs4105144 (CYP2A6) there was higher frequency of T allele carriers in Roma in comparison with Czech population (68.7 vs. 49.8%; p<0.0001). For rs3892097 (CYP2D6) there was more carriers of the A allele between Roma in comparison with Czech population (39.2 vs. 38.2%; p=0.048). Genotype/allelic frequencies of CYP2D6 (rs1065852) and CYP1A2 (rs762551) variants did not significantly differ between the ethnics. Conclusions There were significant differences in allelic/genotype frequencies of some, but not all cytochromes P450 polymorphisms between the Czech Roma/Gypsies and Czech non-Roma subjects.
Collapse
Affiliation(s)
- Lucie Dlouhá
- Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- Department of Anthropology and Human Genetics, Faculty of Science, Charles University, Prague, Czech Republic
| | - Věra Adámková
- Department of Preventive Cardiology for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - Lenka Šedová
- Faculty of Health and Social Sciences, University of South Bohemia, České Budejovice, Czech Republic
| | - Věra Olišarová
- Faculty of Health and Social Sciences, University of South Bohemia, České Budejovice, Czech Republic
| | - Jaroslav A Hubáček
- Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - Valérie Tóthová
- Faculty of Health and Social Sciences, University of South Bohemia, České Budejovice, Czech Republic
| |
Collapse
|
8
|
Mavillard F, Madruga-Garrido M, Rivas E, Servián-Morilla E, Ávila-Polo R, Marcos I, Morón FJ, Paradas C, Cabrera-Serrano M. NOVEL intronic CAPN3 Roma mutation alters splicing causing RNA mediated decay. Ann Clin Transl Neurol 2019; 6:2328-2333. [PMID: 31612648 PMCID: PMC6856619 DOI: 10.1002/acn3.50910] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Revised: 09/02/2019] [Accepted: 09/10/2019] [Indexed: 01/08/2023] Open
Abstract
CAPN3 mutations cause a limb girdle muscular dystrophy. Functional characterization of novel mutations facilitates diagnosis of future cases. We have identified a novel (c.1992 + 2T>G) CAPN3 mutation that disrupts the donor splice site of intron 17 splicing out exon 17, with mRNA levels severely reduced or undetectable. The mutation induces a strong change in the 3D structure of the mRNA which supports no‐go mRNA decay as the probable mechanism for RNA degradation. The mutation was identified in two unrelated Roma individuals showing a common ancestral origin and founder effect. This is the first Roma CAPN3 mutation to be reported.
Collapse
Affiliation(s)
- Fabiola Mavillard
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, Sevilla, Spain.,Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de salud Carlos III, Sevilla, Spain
| | - Marcos Madruga-Garrido
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, Sevilla, Spain.,Neuromuscular Disorder Unit, Pediatric Neurology Department, Hospital U. Virgen del Rocío, Sevilla, Spain
| | - Eloy Rivas
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, Sevilla, Spain.,Department of Pathology, Hospital U. Virgen del Rocío, Sevilla, Spain
| | - Emilia Servián-Morilla
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, Sevilla, Spain.,Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de salud Carlos III, Sevilla, Spain
| | - Rainiero Ávila-Polo
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, Sevilla, Spain.,Department of Pathology, Hospital U. Virgen del Rocío, Sevilla, Spain
| | - Irene Marcos
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, Sevilla, Spain.,Department of Maternal-Fetal Medicine, Genetics and Reproduction, Hospital U. Virgen del Rocío, Sevilla, Spain.,Centro Investigación Biomédica en Red Enfermedades Raras (CIBERER), Seville, Spain
| | - Francisco J Morón
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, Sevilla, Spain
| | - Carmen Paradas
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, Sevilla, Spain.,Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de salud Carlos III, Sevilla, Spain.,Department of Neurology, Hospital Virgen del Rocío, Sevilla, Spain
| | - Macarena Cabrera-Serrano
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, Sevilla, Spain.,Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Instituto de salud Carlos III, Sevilla, Spain.,Department of Neurology, Hospital Virgen del Rocío, Sevilla, Spain
| |
Collapse
|
9
|
Stroek K, Bouva MJ, Schielen PCJI, Vaz FM, Heijboer AC, de Jonge R, Boelen A, Bosch AM. Recommendations for newborn screening for galactokinase deficiency: A systematic review and evaluation of Dutch newborn screening data. Mol Genet Metab 2018; 124:50-56. [PMID: 29580649 DOI: 10.1016/j.ymgme.2018.03.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Revised: 03/19/2018] [Accepted: 03/19/2018] [Indexed: 12/01/2022]
Abstract
INTRODUCTION Galactokinase (GALK) deficiency causes cataract leading to severe developmental consequences unless treated early. Because of the easy prevention and rapid reversibility of cataract with treatment, the Dutch Health Council advised to include GALK deficiency in the Dutch newborn screening program. The aim of this study is to establish the optimal screening method and cut-off value (COV) for GALK deficiency screening by performing a systematic review of the literature of screening strategies and total galactose (TGAL) values and by evaluating TGAL values in the first week of life in a cohort of screened newborns in the Netherlands. METHODS Systematic literature search strategies in OVID MEDLINE and OVID EMBASE were developed and study selection, data collection and analyses were performed by two independent investigators. A range of TGAL values measured by the Quantase Neonatal Total Galactose screening assay in a cohort of Dutch newborns in 2007 was evaluated. RESULTS Eight publications were included in the systematic review. All four studies describing screening strategies used TGAL as the primary screening marker combined with galactose-1-phosphate uridyltransferase (GALT) measurement that is used for classical galactosemia screening. TGAL COVs of 2200 μmol/L, 1665 μmol/L and 1110 μmol/L blood resulted in positive predictive values (PPV) of 100%, 82% and 10% respectively. TGAL values measured in the newborn period were reported for 39 GALK deficiency patients with individual values ranging from 3963 to 8159 μmol/L blood and 2 group values with mean 8892 μmol/L blood (SD ± 5243) and 4856 μmol/L blood (SD ± 461). Dutch newborn screening data of 72,786 newborns from 2007 provided a median TGAL value of 110 μmol/L blood with a range of 30-2431 μmol/L blood. CONCLUSION Based on TGAL values measured in GALK deficiency patients reported in the literature and TGAL measurements in the Dutch cohort by newborn screening we suggest to perform the GALK screening with TGAL as a primary marker with a COV of 2500 μmol/L blood, combined with GALT enzyme activity measurement as used in the classical galactosemia screening, to ensure detection of GALK deficiency patients and minimize false positive referrals.
Collapse
Affiliation(s)
- Kevin Stroek
- Department of Clinical Chemistry, Laboratory of Endocrinology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | - Marelle J Bouva
- Reference Laboratory for Neonatal Screening, Centre for Health Protection, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
| | - Peter C J I Schielen
- Reference Laboratory for Neonatal Screening, Centre for Health Protection, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
| | - Frédéric M Vaz
- Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | - Annemieke C Heijboer
- Department of Clinical Chemistry, Laboratory of Endocrinology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Clinical Chemistry, Endocrine Laboratory, VU University Medical Center, Amsterdam, The Netherlands.
| | - Robert de Jonge
- Department of Clinical Chemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands.
| | - Anita Boelen
- Department of Clinical Chemistry, Laboratory of Endocrinology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| | - Annet M Bosch
- Department of Pediatrics, Division of Metabolic Disorders, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
| |
Collapse
|
10
|
Schuler D, Höll C, Grün N, Ulrich J, Dillner B, Klebl F, Ammon A, Voll LM, Kämper J. Galactose metabolism and toxicity in Ustilago maydis. Fungal Genet Biol 2018; 114:42-52. [PMID: 29580862 DOI: 10.1016/j.fgb.2018.03.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2017] [Revised: 03/07/2018] [Accepted: 03/22/2018] [Indexed: 10/17/2022]
Abstract
In most organisms, galactose is metabolized via the Leloir pathway, which is conserved from bacteria to mammals. Utilization of galactose requires a close interplay of the metabolic enzymes, as misregulation or malfunction of individual components can lead to the accumulation of toxic intermediate compounds. For the phytopathogenic basidiomycete Ustilago maydis, galactose is toxic for wildtype strains, i.e. leads to growth repression despite the presence of favorable carbon sources as sucrose. The galactose sensitivity can be relieved by two independent modifications: (1) by disruption of Hxt1, which we identify as the major transporter for galactose, and (2) by a point mutation in the gene encoding the galactokinase Gal1, the first enzyme of the Leloir pathway. The mutation in gal1(Y67F) leads to reduced enzymatic activity of Gal1 and thus may limit the formation of putatively toxic galactose-1-phosphate. However, systematic deletions and double deletions of different genes involved in galactose metabolism point to a minor role of galactose-1-phosphate in galactose toxicity. Our results show that molecular triggers for galactose toxicity in U. maydis differ from yeast and mammals.
Collapse
Affiliation(s)
- David Schuler
- Karlsruhe Institute of Technology, Institute for Applied Biosciences, Department of Genetics, Fritz Haber Weg 4, 76131 Karlsruhe, Germany
| | - Christina Höll
- Karlsruhe Institute of Technology, Institute for Applied Biosciences, Department of Genetics, Fritz Haber Weg 4, 76131 Karlsruhe, Germany
| | - Nathalie Grün
- Karlsruhe Institute of Technology, Institute for Applied Biosciences, Department of Genetics, Fritz Haber Weg 4, 76131 Karlsruhe, Germany
| | - Jonas Ulrich
- Karlsruhe Institute of Technology, Institute for Applied Biosciences, Department of Genetics, Fritz Haber Weg 4, 76131 Karlsruhe, Germany
| | - Bastian Dillner
- Karlsruhe Institute of Technology, Institute for Applied Biosciences, Department of Genetics, Fritz Haber Weg 4, 76131 Karlsruhe, Germany
| | - Franz Klebl
- FAU Erlangen-Nuremberg, Department of Biology, Molecular Plant Physiology, Staudtstrasse 5, 91058 Erlangen, Germany
| | - Alexandra Ammon
- Philips-University of Marburg, Department of Biology, Plant Physiology and Photo Biology, Karl von Frisch Strasse 8, 35043 Marburg, Germany
| | - Lars M Voll
- Philips-University of Marburg, Department of Biology, Plant Physiology and Photo Biology, Karl von Frisch Strasse 8, 35043 Marburg, Germany
| | - Jörg Kämper
- Karlsruhe Institute of Technology, Institute for Applied Biosciences, Department of Genetics, Fritz Haber Weg 4, 76131 Karlsruhe, Germany.
| |
Collapse
|
11
|
Park KJ, Park S, Lee E, Park JH, Park JH, Park HD, Lee SY, Kim JW. A Population-Based Genomic Study of Inherited Metabolic Diseases Detected Through Newborn Screening. Ann Lab Med 2017; 36:561-72. [PMID: 27578510 PMCID: PMC5011110 DOI: 10.3343/alm.2016.36.6.561] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2016] [Revised: 05/11/2016] [Accepted: 06/27/2016] [Indexed: 01/29/2023] Open
Abstract
Background A newborn screening (NBS) program has been utilized to detect asymptomatic newborns with inherited metabolic diseases (IMDs). There have been some bottlenecks such as false-positives and imprecision in the current NBS tests. To overcome these issues, we developed a multigene panel for IMD testing and investigated the utility of our integrated screening model in a routine NBS environment. We also evaluated the genetic epidemiologic characteristics of IMDs in a Korean population. Methods In total, 269 dried blood spots with positive results from current NBS tests were collected from 120,700 consecutive newborns. We screened 97 genes related to NBS in Korea and detected IMDs, using an integrated screening model based on biochemical tests and next-generation sequencing (NGS) called NewbornSeq. Haplotype analysis was conducted to detect founder effects. Results The overall positive rate of IMDs was 20%. We identified 10 additional newborns with preventable IMDs that would not have been detected prior to the implementation of our NGS-based platform NewbornSeq. The incidence of IMDs was approximately 1 in 2,235 births. Haplotype analysis demonstrated founder effects in p.Y138X in DUOXA2, p.R885Q in DUOX2, p.Y439C in PCCB, p.R285Pfs*2 in SLC25A13, and p.R224Q in GALT. Conclusions Through a population-based study in the NBS environment, we highlight the screening and epidemiological implications of NGS. The integrated screening model will effectively contribute to public health by enabling faster and more accurate IMD detection through NBS. This study suggested founder mutations as an explanation for recurrent IMD-causing mutations in the Korean population.
Collapse
Affiliation(s)
- Kyoung Jin Park
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea
| | | | | | - Jong Ho Park
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea
| | - June Hee Park
- Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
| | - Hyung Doo Park
- Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Soo Youn Lee
- Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Jong Won Kim
- Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea.,Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
| |
Collapse
|
12
|
Messina-Baas O, Cuevas-Covarrubias SA. Inherited Congenital Cataract: A Guide to Suspect the Genetic Etiology in the Cataract Genesis. Mol Syndromol 2017; 8:58-78. [PMID: 28611546 DOI: 10.1159/000455752] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/05/2016] [Indexed: 01/23/2023] Open
Abstract
Cataracts are the principal cause of treatable blindness worldwide. Inherited congenital cataract (CC) shows all types of inheritance patterns in a syndromic and nonsyndromic form. There are more than 100 genes associated with cataract with a predominance of autosomal dominant inheritance. A cataract is defined as an opacity of the lens producing a variation of the refractive index of the lens. This variation derives from modifications in the lens structure resulting in light scattering, frequently a consequence of a significant concentration of high-molecular-weight protein aggregates. The aim of this review is to introduce a guide to identify the gene involved in inherited CC. Due to the manifold clinical and genetic heterogeneity, we discarded the cataract phenotype as a cardinal sign; a 4-group classification with the genes implicated in inherited CC is proposed. We consider that this classification will assist in identifying the probable gene involved in inherited CC.
Collapse
|
13
|
Abstract
Galactokinase catalyses the first committed step of the Leloir pathway, i.e. the ATP-dependent phosphorylation of α-D-galactose at C1-OH. Reduced galactokinase activity results in the inherited metabolic disease type II galactosaemia. However, inhibition of galactokinase is considered a viable approach to treating more severe forms of galactosaemia (types I and III). Considerable progress has been made in the identification of high affinity, selective inhibitors. Although the structure of galactokinase from a variety of species is known, its catalytic mechanism remains uncertain. Although the bulk of evidence suggests that the reaction proceeds via an active site base mechanism, some experimental and theoretical studies contradict this. The enzyme has potential as a biocatalyst in the production of sugar 1-phosphates. This potential is limited by its high specificity. A variety of approaches have been taken to identify galactokinase variants which are more promiscuous. These have broadened galactokinase's specificity to include a wide range of D- and L-sugars. Initial studies suggest that some of these alterations result in increased flexibility at the active site. It is suggested that modulation of protein flexibility is at least as important as structural modifications in determining the success or failure of enzyme engineering.
Collapse
|
14
|
Tournev I. The Meryon Lecture at the 18th Annual Meeting of the Meryon Society Wolfson College, Oxford, UK, 12th September 2014: Neuromuscular disorders in Roma (Gypsies)--collaborative studies, epidemiology, community-based carrier testing program and social activities. Neuromuscul Disord 2015; 26:94-103. [PMID: 26564278 DOI: 10.1016/j.nmd.2015.10.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2015] [Revised: 09/29/2015] [Accepted: 10/06/2015] [Indexed: 02/07/2023]
Affiliation(s)
- Ivailo Tournev
- Department of Neurology, Sofia Medical University, Sofia, Bulgaria; Department of Cognitive Science and Psychology, New Bulgarian University, Sofia, Bulgaria; Ethnic Minorities Health Problems Foundation, Sofia, Bulgaria.
| |
Collapse
|
15
|
Janicsek I, Sipeky C, Bene J, Duga B, Melegh BI, Melegh B, Sümegi K, Jaromi L, Magyari L, Melegh B. Significant interethnic differencies in functional variants of PON1 and P2RY12 genes in Roma and Hungarian population samples. Mol Biol Rep 2014; 42:227-32. [PMID: 25297118 DOI: 10.1007/s11033-014-3762-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2012] [Accepted: 09/19/2014] [Indexed: 11/28/2022]
Abstract
Antiplatelet therapy with clopidogrel is one of the most common therapies given to patients worldwide. However, the clinical efficacy and toxicity of clopidogrel is not constant in every patient due to interindividual variations. There are several factors that contribute to these interindividual differencies such as SNPs in genes of specific receptors and enzymes. PON1 (paraoxonase 1) plays an important role in the bioactivation of clopidogrel. Single nucleotide polymorphisms of this gene decrease the activity of paraoxonase enzyme and lead to an unefficient clopidogrel effect. P2RY12 (purinergic receptor P2Y, G-protein coupled, 12) gene is coding a receptor, which is situated on the surface of the platelets and plays a role in ADP-induced platelet aggregation. In this study we investigated 2 functional SNPs of PON1 gene (rs662 and rs854560) and 3 variants of the P2RY12 gene (rs2046934, rs6798347, rs6801273) in samples pooled from average Hungarian Roma and Hungarian population samples with PCR-RFLP method. For the PON1 variants we detected that the R allele frequency was significantly lower in the Roma group compared to the Hungarian population. (0.249 vs 0.318 p < 0.001). By contrast, the frequency of the M allele was significantly higher in Roma than in Hungarians (0.332 vs 0.290 p < 0.05). For the 3 P2RY12 variants we could find significant differencies only in rs2046934: the frequency of the CC genotype is 7 times higher in Hungarians than in Romas (1.4 vs 0.2 %, p < 0.05). The data presented here represent a unique genetic profile in Roma people that has not been reported for other populations.
Collapse
Affiliation(s)
- Ingrid Janicsek
- Department of Medical Genetics, Szentágothai János Research Center, Clinical Center, University of Pécs, Szigeti 12, Pécs, 7624, Hungary,
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Richard Gitzelmann (23rd February 1930--31st October 2013). Eur J Pediatr 2014; 173:695-7. [PMID: 24770547 DOI: 10.1007/s00431-014-2322-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/10/2014] [Accepted: 04/10/2014] [Indexed: 10/25/2022]
|
17
|
Pyhtila BM, Shaw KA, Neumann SE, Fridovich-Keil JL. Newborn screening for galactosemia in the United States: looking back, looking around, and looking ahead. JIMD Rep 2014; 15:79-93. [PMID: 24718839 DOI: 10.1007/8904_2014_302] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2014] [Revised: 02/05/2014] [Accepted: 02/14/2014] [Indexed: 12/17/2022] Open
Abstract
It has been 50 years since the first newborn screening (NBS) test for galactosemia was conducted in Oregon, and almost 10 years since the last US state added galactosemia to their NBS panel. During that time an estimated >2,500 babies with classic galactosemia have been identified by NBS. Most of these infants were spared the trauma of acute disease by early diagnosis and intervention, and many are alive today because of NBS. Newborn screening for galactosemia is a success story, but not yet a story with a completely happy ending. NBS, follow-up testing, and intervention for galactosemia continue to present challenges that highlight gaps in our knowledge. Here we compare galactosemia screening and follow-up data from 39 NBS programs gathered from the states directly or from public sources. On some matters the programs agreed: for example, those providing relevant data all identify classic galactosemia in close to 1/50,000 newborns and recommend immediate and lifelong dietary restriction of galactose for those infants. On other matters the programs disagree. For example, Duarte galactosemia (DG) detection rates vary dramatically among states, largely reflecting differences in screening approach. For infants diagnosed with DG, >80% of the programs surveyed recommend complete or partial dietary galactose restriction for the first year of life, or give mixed recommendations; <20% recommend no intervention. This disparity presents an ongoing dilemma for families and healthcare providers that could and should be resolved.
Collapse
Affiliation(s)
- Brook M Pyhtila
- Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, 30322, USA
| | | | | | | |
Collapse
|
18
|
Gabrikova D, Mistrik M, Bernasovska J, Bozikova A, Behulova R, Tothova I, Macekova S. Founder mutations in NDRG1 and HK1 genes are common causes of inherited neuropathies among Roma/Gypsies in Slovakia. J Appl Genet 2013; 54:455-60. [PMID: 23996628 DOI: 10.1007/s13353-013-0168-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2013] [Revised: 08/13/2013] [Accepted: 08/20/2013] [Indexed: 11/29/2022]
Abstract
Autosomal recessive forms of Charcot-Marie-Tooth disease (CMT) account for less than 10 % of all CMT cases, but are more frequent in the populations with a high rate of consanguinity. Roma (Gypsies) are a transnational minority with an estimated population of 10 to 14 million, in which a high degree of consanguineous marriages is a generally known fact. Similar to the other genetically isolated founder populations, the Roma harbour a number of unique or rare autosomal recessive disorders, caused by "private" founder mutations. There are three subtypes of autosomal recessive CMT with mutations private to the Roma population: CMT4C, CMT4D and CMT4G. We report on the molecular examination of four families of Roma origin in Slovakia with early-onset demyelinating neuropathy and autosomal recessive inheritance. We detected mutation p.R148X (g.631C>T) in the NDRG1 (NM_006096.3) gene in two families and mutation g.9712G>C in the HK1 (NM_033498) gene in the other two families. These mutations cause CMT4D and CMT4G, respectively. The success of molecular genetic analysis in all families confirms that autosomal recessive forms of CMT caused by mutations on the NDRG1 and HK1 genes are common causes of inherited neuropathies among Slovak Roma. Providing genetic analysis of these genes for patients with Roma origin as a common part of diagnostic procedure would contribute to a better rate of diagnosed cases of demyelinating neuropathy in Slovakia and in other countries with a Roma minority.
Collapse
Affiliation(s)
- Dana Gabrikova
- Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Ul. 17. Novembra 1, 08116, Presov, Slovakia,
| | | | | | | | | | | | | |
Collapse
|
19
|
Bayarchimeg M, Ismail D, Lam A, Burk D, Kirk J, Hogler W, Flanagan SE, Ellard S, Hussain K. Galactokinase deficiency in a patient with congenital hyperinsulinism. JIMD Rep 2013; 5:7-11. [PMID: 23430910 DOI: 10.1007/8904_2011_110] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2011] [Revised: 09/14/2011] [Accepted: 10/25/2011] [Indexed: 10/14/2022] Open
Abstract
BACKGROUND Galactokinase catalyses the first committed step in galactose metabolism, the conversion of galactose to galactose-1-phosphate. Galactokinase deficiency is an extremely rare form of galactosaemia, and the most frequent complication reported is cataracts. Congenital hyperinsulinism (CHI) is a cause of severe hypoglycaemia in the newborn period. Galactosaemia has not previously been reported in a neonate with concomitant CHI. AIMS To report the first case of a patient with CHI and galactokinase deficiency, and to describe the diagnostic pitfalls with bedside blood glucose testing in a neonate with combined galactokinase deficiency and CHI. PATIENTS/METHODS A 3-day-old baby girl from consanguineous parents presented with poor feeding, irritability and seizures. Capillary blood glucose testing using bedside test strips and glucometer showed a glucose level of 18 mmol/L, but the actual laboratory blood glucose level was only 1.8 mmol/L. After discontinuation of oral feeding (stopping provision of dietary galactose), the bedside capillary blood glucose correlated with laboratory glucose concentrations. RESULTS Biochemically the patient had CHI (blood glucose level 2.3 mmol/L with simultaneous serum insulin level of 30 mU/L) and galactokinase deficiency (elevated serum galactose level 0.62 μmol/L). Homozygous loss of function mutations in ABCC8 and GALK1 were found, which explained the patient's CHI and galactokinase deficiency, respectively. CONCLUSION This is the first reported case of CHI and galactokinase deficiency occurring in the same patient. Severe hypoglycaemia in neonates with CHI may go undetected with bedside blood glucose meters in patients with galactokinase deficiency.
Collapse
Affiliation(s)
- Mashbat Bayarchimeg
- Department of Endocrinology, Great Ormond Street Hospital for Children NHS Trust, London, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Zajc Petranović M, Skarić-Jurić T, Smolej Narančić N, Tomas Z, Krajačić P, Miličić J, Barbalić M, Tomek-Roksandić S. Angiotensin-converting enzyme deletion allele is beneficial for the longevity of Europeans. AGE (DORDRECHT, NETHERLANDS) 2012; 34:583-595. [PMID: 21614448 PMCID: PMC3337925 DOI: 10.1007/s11357-011-9270-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/10/2011] [Accepted: 05/09/2011] [Indexed: 05/30/2023]
Abstract
The human angiotensin converting enzyme (ACE) gene is one of the most investigated candidate genes for cardiovascular diseases (CVD), but the understanding of its role among the elderly is vague. Therefore, this study focuses at: (a) testing the association of ACE polymorphism with CVD risk factors among the elderly, and (b) detecting the possible unequal distribution of ACE genotypes between senescent and younger segments of the European populations. The association of ACE I/D polymorphism with CVD health status [hypertension (HT), obesity, dislypidemia] in 301 very old subjects (88.2 ± 5 years; F/M = 221/80) was tested by means of logistic regression analysis. The meta-analysis of D allele frequency in general vs. elderly (80+ years) groups was conducted using all publicly available data for European populations comprising both age cohorts. Multiple multinomial logistic regression revealed that within this elderly sample, age (younger olds, 80-90 years), female sex (OR = 3.13, 95% CI = 1.59-6.19), and elevated triglycerides (OR = 2.53, 95% CI = 1.29-4.95) were positively associated with HT, while ACE polymorphism was not. It was also established that the DD genotype was twice as high in 80+ cohort compared to general population of Croatia (p < 0.00001). This trend was confirmed by the meta-analysis that showed higher D allele frequencies in olds from nine of ten considered European populations (OR = 1.19, 95% CI = 1.08-1.31). The data in elderly cohort do not confirm previously reported role of ACE DD genotype to the development of HT. Moreover, meta-analysis indicated that ACE D allele has some selective advantage that contributes to longevity in majority of European populations.
Collapse
|
21
|
Singh R, Ram J, Kaur G, Prasad R. Galactokinase deficiency induced cataracts in Indian infants: identification of 4 novel mutations in GALK gene. Curr Eye Res 2012; 37:949-54. [PMID: 22632133 DOI: 10.3109/02713683.2012.688162] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
PURPOSE To establish the incidence and molecular basis of type II galactosemia in Indian infants presenting with congenital cataracts. METHODS 200 infants with congenital cataracts were screed for galactokinase (GALK) enzyme deficiency. GALK enzyme activity was measured using radioactive galactose-1-(14)C and mutations were studied using polymerase chain reaction (PCR), single strand conformational polymorphism (SSCP) and subsequent DNA sequencing. RESULTS 16 (8%) out of 200 infants with congenital cataracts were found to be GALK deficient with male: female:: 9:7. A significantly reduced GALK activity of 0.13 ± 0.04 µmoles/h/mL was observed in the galactosemia patients compared to 0.232 ± 0.07 µmoles/h/mL in the normal controls. A total of 5 distinct mutations were identified in GALK gene in five different patients out of which four were novel mutations viz. S79F, S79Y, S205S and F275Y. The functional significance of the mutations and splicing defects associated with them were investigated using different computer based applications. CONCLUSION The study highlighted the importance of GALK gene analysis in diagnosis of galactosemia in Indian population. It also revealed that the mutational profile of Indian GALK patients differs significantly from other populations studied. Low mutation detection rate observed in this study may be due to the fact that SSCP is a quite indirect and non-fullproof method of mutation detection.
Collapse
Affiliation(s)
- Ramandeep Singh
- Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | | | | | | |
Collapse
|
22
|
Janzen N, Illsinger S, Meyer U, Shin YS, Sander J, Lücke T, Das AM. Early cataract formation due to galactokinase deficiency: impact of newborn screening. Arch Med Res 2011; 42:608-12. [PMID: 22154682 DOI: 10.1016/j.arcmed.2011.11.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2011] [Accepted: 11/04/2011] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND AIMS Galactokinase (GALK) deficiency is an autosomal recessive disorder causing cataract formation that can be prevented or mitigated by early diagnosis and galactose-restricted diet. The aim of this retrospective study was to explore whether GALK-deficiency meets the criteria for neonatal mass screening programs. METHODS From 2000 until 2010, the Screening Laboratory Hannover performed newborn screening in 1,950,927 infants from Germany for galactosemia by measuring galactose-1-phosphate-uridyl-transferase and total galactose concentration (free galactose plus galactose-1-phosphate), including automatic screening for GALK deficiency. RESULTS Eleven cases were found with elevated galactose levels accompanied by normal transferase activity. Nine of 11 cases were informative; the diagnosis was established by demonstrating deficient activity of the GALK enzyme in erythrocytes. To our knowledge, screening did not produce any false negative results. All patients were treated with a galactose-restricted diet from the neonatal period or infancy. Three of nine patients suffered from congenital cataracts or eventual development of cataracts, despite normal galactose concentrations in blood. CONCLUSIONS Newborn screening for GALK deficiency prevents or at least mitigates cataract formation. As screening for GALK deficiency is technically simple, it seems to be reasonable to include this disorder in routine screening programs by simultaneous determination of transferase activity and quantification of galactose plus galactose-1-phosphate in dried blood spots.
Collapse
Affiliation(s)
- Nils Janzen
- Clinic for Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany.
| | | | | | | | | | | | | |
Collapse
|
23
|
Churchill A, Graw J. Clinical and experimental advances in congenital and paediatric cataracts. Philos Trans R Soc Lond B Biol Sci 2011; 366:1234-49. [PMID: 21402583 DOI: 10.1098/rstb.2010.0227] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Cataracts (opacities of the lens) are frequent in the elderly, but rare in paediatric practice. Congenital cataracts (in industrialized countries) are mainly caused by mutations affecting lens development. Much of our knowledge about the underlying mechanisms of cataractogenesis has come from the genetic analysis of affected families: there are contributions from genes coding for transcription factors (such as FoxE3, Maf, Pitx3) and structural proteins such as crystallins or connexins. In addition, there are contributions from enzymes affecting sugar pathways (particularly the galactose pathway) and from a quite unexpected area: axon guidance molecules like ephrins and their receptors. Cataractous mouse lenses can be identified easily by visual inspection, and a remarkable number of mutant lines have now been characterized. Generally, most of the mouse mutants show a similar phenotype to their human counterparts; however, there are some remarkable differences. It should be noted that many mutations affect genes that are expressed not only in the lens, but also in tissues and organs outside the eye. There is increasing evidence for pleiotropic effects of these genes, and increasing consideration that cataracts may act as early and readily detectable biomarkers for a number of systemic syndromes.
Collapse
|
24
|
Hennermann JB, Schadewaldt P, Vetter B, Shin YS, Mönch E, Klein J. Features and outcome of galactokinase deficiency in children diagnosed by newborn screening. J Inherit Metab Dis 2011; 34:399-407. [PMID: 21290184 DOI: 10.1007/s10545-010-9270-8] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2010] [Revised: 12/13/2010] [Accepted: 12/23/2010] [Indexed: 10/18/2022]
Abstract
Galactokinase deficiency (GALK-D), an autosomal recessive disorder in the Leloir pathway, results in accumulation of galactose, galactitol, and galactonate and leads to early onset of juvenile bilateral cataract. Highest incidence of GALK-D is found in Romani populations. The migration wave due to the Yugoslavian civil war has changed the spectrum of inborn errors of metabolism within Europe. Hence, newborn screening (NBS) in the Berlin region, performed from 1991 until 2010 in 683,675 neonates, revealed an increased incidence of GALK-D of 1:40,000, comparable to that of galactose-1-phosphate-uridyltransferase deficiency. A total of 44% of GALK-D patients were of Romani origin. All patients of Bosnian or Serbian origin were homozygous for the Romani founder mutation p.P28T. Detection of GALK-D by NBS and early start of galactose-restricted diet resulted in regression or prevention of cataracts. Slight cataracts without visual impairment occurred in 50% of the patients, 56% of whom were noncompliant. Further clinical symptoms, e.g., hypoglycemia, mental retardation, microcephaly, and failure to thrive, were associated with noncompliance. With treatment, galactose in blood decreased from 8,892 ± 5,243 to 36.5 ± 49.3 μmol/l, galactose in urine from 31,820 ± 32,103 to 30.0 ± 36.1 μmol/mmol creatinine, galactitol in RBC from 1,584 ± 584 to 12.3 ± 9.4 μmol/l, and galactitol in urine from 11,724 ± 4,496 to 236 ± 116 μmol/mmol creatinine. This is the first presentation of outcome and clinical features in GALK-D patients diagnosed by NBS. As our data suggest, GALK-D should be considered for inclusion in NBS in populations expected to have substantial numbers of GALK-D carriers, e.g., Yugoslavian immigrants.
Collapse
Affiliation(s)
- Julia B Hennermann
- Department of Pediatrics, Charité Universitätsmedizin Berlin, Berlin, Germany.
| | | | | | | | | | | |
Collapse
|
25
|
Jójárt B, Szőri M, Izsák R, Marsi I, László A, Csizmadia IG, Viskolcz B. The effect of a Pro28Thr point mutation on the local structure and stability of human galactokinase enzyme—a theoretical study. J Mol Model 2011; 17:2639-49. [DOI: 10.1007/s00894-011-0958-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2010] [Accepted: 01/04/2011] [Indexed: 11/24/2022]
|
26
|
Abstract
In most organisms, productive utilization of galactose requires the highly conserved Leloir pathway of galactose metabolism. Yet, if this metabolic pathway is perturbed due to congenital deficiencies of the three associated enzymes, or an overwhelming presence of galactose, this monosaccharide which is abundantly present in milk and many non-dairy foodstuffs, will become highly toxic to humans and animals. Despite more than four decades of intense research, little is known about the molecular mechanisms of galactose toxicity in human patients and animal models. In this contemporary review, we take a unique approach to present an overview of galactose toxicity resulting from the three known congenital disorders of galactose metabolism and from experimental hypergalactosemia. Additionally, we update the reader about research progress on animal models, as well as advances in clinical management and therapies of these disorders.
Collapse
Affiliation(s)
- Kent Lai
- Division of Medical Genetics, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT 84132, USA.
| | | | | |
Collapse
|
27
|
Park HD, Kim YK, Park KU, Kim JQ, Song YH, Song J. A novel c.-22T>C mutation in GALK1 promoter is associated with elevated galactokinase phenotype. BMC MEDICAL GENETICS 2009; 10:29. [PMID: 19309526 PMCID: PMC2667498 DOI: 10.1186/1471-2350-10-29] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/07/2008] [Accepted: 03/24/2009] [Indexed: 11/10/2022]
Abstract
Background Many genetic variations of GALK1 have been identified in the patients with galactokinase (GALK1) deficiency. However, the molecular characteristics of GALK1 in individuals with elevated GALK1 activity are relatively unknown. Methods We investigated the relationship between elevated GALK1 activity and the molecular GALK1 gene variations, and the molecular mechanism underlying elevated GALK1 activity. PCR products from 63 subjects, without any attenuation of galactose degradation enzymes, were sequenced to screen for nucleotide alterations in the GALK1 promoter. Results Three nucleotide substitutions were identified: c.-179A>G, c.-27A>C, and c.-22T>C. With respect to the c.-22T>C mutation, GALK1 activity in 13 subjects with the T/C or C/C genotype was significantly higher than those in 50 subjects with the T/T genotype (p < 0.001). The dual luciferase reporter assay in Hep3B cells showed that the luciferase activity with the GALK1 promoter with the c.-22C mutant allele increased approximately 2.5-fold, compared to that with the c.-22T. A specific DNA-protein complex was observed in an electrophoretic mobility shift assay, with slightly higher affinity to c.-22C than to c.-22T. Conclusion The c.-22T>C mutation, which was observed frequently in individuals with elevated GALK1 activity, increased the expression of a reporter gene through enhanced binding of a currently unidentified nuclear protein. These results suggest that the elevated GALK1 activity resulted from enhanced gene expression, due to nucleotide variation within GALK1 promoter.
Collapse
Affiliation(s)
- Hyung-Doo Park
- Ilsong Institute of Life Science, Hallym University, Anyang, Korea.
| | | | | | | | | | | |
Collapse
|
28
|
Sahai MA, Viskolcz B, Pai EF, Csizmadia IG. Quantifying the Intrinsic Effects of Two Point Mutation Models of Proline−Proline Diamino Acid Diamide: A First-Principle Computational Study. J Phys Chem B 2007; 111:11592-602. [PMID: 17824687 DOI: 10.1021/jp073471h] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Two sites of a Pro-Pro diamide were subjected to individual Pro --> Thr point mutations. The parent diamide Pro-Pro as well as selected conformers of the Pro-Thr and Thr-Pro mutant models were subjected to molecular computations at the B3LYP/6-31G(d) level of theory. At the optimized geometries, thermodynamic functions (S, H, and G) were computed. In order to assess relative stabilities of the mutant models, isodesmic reactions were constructed to calculate DeltaS, DeltaH, and DeltaG, relative to the initial Pro-Pro state. The importance of intramolecular hydrogen bonds, involving the -OH group of the Thr side chain, which emerged after the point mutations were also examined. Our findings suggest a novel approach to analyzing the stability of point mutants in peptide models through the analysis of thermodynamic functions.
Collapse
Affiliation(s)
- Michelle A Sahai
- Ontario Cancer Institute, Division of Cancer Genomics and Proteomics, MaRS Center, Toronto Medical Discovery Tower, 101 College Street, Room 5-359, Toronto, Ontario, M5G 1L7, Canada.
| | | | | | | |
Collapse
|
29
|
Park HD, Bang YL, Park KU, Kim JQ, Jeong BH, Kim YS, Song YH, Song J. Molecular and biochemical characterization of the GALK1 gene in Korean patients with galactokinase deficiency. Mol Genet Metab 2007; 91:234-8. [PMID: 17517531 DOI: 10.1016/j.ymgme.2007.04.005] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2007] [Revised: 04/06/2007] [Accepted: 04/06/2007] [Indexed: 11/26/2022]
Abstract
Galactokinase (GALK) deficiency is an autosomal recessive disorder characterized by elevation of blood galactose concentration and diminished galactose-1-phosphate, leading to the production of galactitol. To investigate the molecular defects of GALK1 gene and the biochemical characteristics of their mutant proteins, PCR-direct sequencing and in vitro expression analysis in Cos7 cells were performed in five Korean patients with GALK deficiency galactosemia. Four missense mutations (p.G137R, p.R256W, p.R277Q, and p.V281M) and one small insertion (c.850_851insG) were identified. Among four patients with severely reduced GALK activity, two were found to be homozygotes for p.R256W and the other two were compound heterozygotes for different molecular defects (p.G137R/p.R277Q and p.V281M/c.850_851insG). One Patient with moderately decreased GALK activity was heterozygous for p.R256W. Expression analysis in Cos7 cells confirmed that each of the mutations resulted in reduction of GALK activity and caused GALK deficiency.
Collapse
Affiliation(s)
- Hyung-Doo Park
- Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Kalaydjieva L. Congenital cataracts-facial dysmorphism-neuropathy. Orphanet J Rare Dis 2006; 1:32. [PMID: 16939648 PMCID: PMC1563997 DOI: 10.1186/1750-1172-1-32] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2006] [Accepted: 08/29/2006] [Indexed: 02/07/2023] Open
Abstract
Congenital Cataracts Facial Dysmorphism Neuropathy (CCFDN) syndrome is a complex developmental disorder of autosomal recessive inheritance. To date, CCFDN has been found to occur exclusively in patients of Roma (Gypsy) ethnicity; over 100 patients have been diagnosed. Developmental abnormalities include congenital cataracts and microcorneae, primary hypomyelination of the peripheral nervous system, impaired physical growth, delayed early motor and intellectual development, mild facial dysmorphism and hypogonadism. Para-infectious rhabdomyolysis is a serious complication reported in an increasing number of patients. During general anaesthesia, patients with CCFDN require careful monitoring as they have an elevated risk of complications. CCFDN is a genetically homogeneous condition in which all patients are homozygous for the same ancestral mutation in the CTDP1 gene. Diagnosis is clinical and is supported by electrophysiological and brain imaging studies. The major differential diagnosis is Marinesco-Sjögren syndrome. The definitive diagnosis is molecular, based on homozygosity for the CTDP1 mutation. CTDP1 maps to 18qter and encodes a protein phosphatase whose only known substrate is the phosphorylated serine residues of the carboxy-terminal domain of the largest subunit of RNA polymerase II, indicating that CCFDN affects basic cellular processes of gene expression and developmental regulation. Families benefit from genetic counselling and predictive testing. Management includes surgical treatment of the cataracts, and rehabilitation and corrective orthopaedic surgery for the peripheral neuropathy. Thus, the most disabling manifestations, though not curable, are manageable, and allow an acceptable quality of life and everyday living. Current data indicate that patients survive well into adulthood.
Collapse
Affiliation(s)
- Luba Kalaydjieva
- Western Australian Institute for Medical Research and Centre for Medical Research, The University of Western Australia, Hospital Avenue, WA 6009 Nedlands, Australia.
| |
Collapse
|
31
|
Todorov T, Savov A, Jelev H, Panteleeva E, Konstantinova D, Krustev Z, Mihaylova V, Tournev I, Tankova L, Tzolova N, Kremensky I. Spectrum of mutations in the Wilson disease gene (ATP7B) in the Bulgarian population. Clin Genet 2005; 68:474-6. [PMID: 16207219 DOI: 10.1111/j.1399-0004.2005.00516.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Kalaydjieva L, Morar B, Chaix R, Tang H. A newly discovered founder population: the Roma/Gypsies. Bioessays 2005; 27:1084-94. [PMID: 16163730 DOI: 10.1002/bies.20287] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The Gypsies (a misnomer, derived from an early legend about Egyptian origins) defy the conventional definition of a population: they have no nation-state, speak different languages, belong to many religions and comprise a mosaic of socially and culturally divergent groups separated by strict rules of endogamy. Referred to as "the invisible minority", the Gypsies have for centuries been ignored by Western medicine, and their genetic heritage has only recently attracted attention. Common origins from a small group of ancestors characterise the 8-10 million European Gypsies as an unusual trans-national founder population, whose exodus from India played the role of a profound demographic bottleneck. Social and economic pressures within Europe led to gradual fragmentation, generating multiple genetically differentiated subisolates. The string of population bottlenecks and founder effects have shaped a unique genetic profile, whose potential for genetic research can be met only by study designs that acknowledge cultural tradition and self-identity.
Collapse
Affiliation(s)
- Luba Kalaydjieva
- Western Australian Institute for Medical Research and Centre for Medical Research, The University of Western Australia, Nedlands, Perth, Australia.
| | | | | | | |
Collapse
|
33
|
Thoden JB, Timson DJ, Reece RJ, Holden HM. Molecular structure of human galactokinase: implications for type II galactosemia. J Biol Chem 2004; 280:9662-70. [PMID: 15590630 DOI: 10.1074/jbc.m412916200] [Citation(s) in RCA: 86] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Galactokinase functions in the Leloir pathway for galactose metabolism by catalyzing the MgATP-dependent phosphorylation of the C-1 hydroxyl group of alpha-D-galactose. The enzyme is known to belong to the GHMP superfamily of small molecule kinases and has attracted significant research attention for well over 40 years. Approximately 20 mutations have now been identified in human galactokinase, which result in the diseased state referred to as Type II galactosemia. Here we report the three-dimensional architecture of human galactokinase with bound alpha-D-galactose and Mg-AMPPNP. The overall fold of the molecule can be described in terms of two domains with the active site wedged between them. The N-terminal domain is dominated by a six-stranded mixed beta-sheet whereas the C-terminal motif contains six alpha-helices and two layers of anti-parallel beta-sheet. Those residues specifically involved in sugar binding include Arg37, Glu43, His44, Asp46, Gly183, Asp186, and Tyr236. The C-1 hydroxyl group of alpha-D-galactose sits within 3.3 A of the gamma-phosphorus of the nucleotide and 3.4 A of the guanidinium group of Arg37. The carboxylate side chain of Asp186 lies within approximately 3.2 A of the C-2 hydroxyl group of alpha-D-galactose and the guanidinium group of Arg37. Both Arg37 and Asp186 are strictly conserved among both prokaryotic and eukaryotic galactokinases. In addition to providing molecular insight into the active site geometry of the enzyme, the model also provides a structural framework upon which to more fully understand the consequences of the those mutations known to give rise to Type II galactosemia.
Collapse
Affiliation(s)
- James B Thoden
- Department of Biochemistry, University of Wisconsin, Madison, Wisconsin 53706, USA
| | | | | | | |
Collapse
|
34
|
Chaix R, Austerlitz F, Morar B, Kalaydjieva L, Heyer E. Vlax Roma history: what do coalescent-based methods tell us? Eur J Hum Genet 2004; 12:285-92. [PMID: 14760363 DOI: 10.1038/sj.ejhg.5201126] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Three coalescent-based methods allowed us to infer some aspects of the history of three Bulgarian Gypsies populations belonging to the Vlax linguistic group: the Lom, Rudari and Kalderas. We used several kinds of genetic markers: HV1 sequences of the maternally inherited mitochondrial genome and microsatellites of the paternally inherited Y chromosome and of the biparentally inherited chromosome 8. This allowed us to infer several parameters for men and women: the splitting order of the populations and the ages of the splitting events, the growth rate in each population and the migration rates between populations. Altogether, they enabled us to infer a demographic scenario that could explain the genetic diversity of Vlax Roma: recent splits occurring after the arrival in Europe, asymmetric migration flows especially for males and unequal growth rates. This represents a considerable contribution to the Vlax Roma history in comparison with the inferences from classical population genetics.
Collapse
Affiliation(s)
- R Chaix
- Equipe de Génétique des Populations, Unité d'Eco-Anthropologie, Musée de l'Homme, Paris, France.
| | | | | | | | | |
Collapse
|
35
|
Morar B, Gresham D, Angelicheva D, Tournev I, Gooding R, Guergueltcheva V, Schmidt C, Abicht A, Lochmüller H, Tordai A, Kalmár L, Nagy M, Karcagi V, Jeanpierre M, Herczegfalvi A, Beeson D, Venkataraman V, Warwick Carter K, Reeve J, de Pablo R, Kučinskas V, Kalaydjieva L. Mutation history of the roma/gypsies. Am J Hum Genet 2004; 75:596-609. [PMID: 15322984 PMCID: PMC1182047 DOI: 10.1086/424759] [Citation(s) in RCA: 126] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2004] [Accepted: 07/20/2004] [Indexed: 11/03/2022] Open
Abstract
The 8-10 million European Roma/Gypsies are a founder population of common origins that has subsequently split into multiple socially divergent and geographically dispersed Gypsy groups. Unlike other founder populations, whose genealogy has been extensively documented, the demographic history of the Gypsies is not fully understood and, given the lack of written records, has to be inferred from current genetic data. In this study, we have used five disease loci harboring private Gypsy mutations to examine some missing historical parameters and current structure. We analyzed the frequency distribution of the five mutations in 832-1,363 unrelated controls, representing 14 Gypsy populations, and the diversification of chromosomal haplotypes in 501 members of affected families. Sharing of mutations and high carrier rates supported a strong founder effect, and the identity of the congenital myasthenia 1267delG mutation in Gypsy and Indian/Pakistani chromosomes provided the best evidence yet of the Indian origins of the Gypsies. However, dramatic differences in mutation frequencies and haplotype divergence and very limited haplotype sharing pointed to strong internal differentiation and characterized the Gypsies as a founder population comprising multiple subisolates. Using disease haplotype coalescence times at the different loci, we estimated that the entire Gypsy population was founded approximately 32-40 generations ago, with secondary and tertiary founder events occurring approximately 16-25 generations ago. The existence of multiple subisolates, with endogamy maintained to the present day, suggests a general approach to complex disorders in which initial gene mapping could be performed in large families from a single Gypsy group, whereas fine mapping would rely on the informed sampling of the divergent subisolates and searching for the shared genomic region that displays the strongest linkage disequilibrium with the disease.
Collapse
Affiliation(s)
- Bharti Morar
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - David Gresham
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Dora Angelicheva
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Ivailo Tournev
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Rebecca Gooding
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Velina Guergueltcheva
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Carolin Schmidt
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Angela Abicht
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Hanns Lochmüller
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Attila Tordai
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Lajos Kalmár
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Melinda Nagy
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Veronika Karcagi
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Marc Jeanpierre
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Agnes Herczegfalvi
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - David Beeson
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Viswanathan Venkataraman
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Kim Warwick Carter
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Jeff Reeve
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Rosario de Pablo
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Vaidutis Kučinskas
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| | - Luba Kalaydjieva
- Laboratories of Molecular Genetics and Genetic Epidemiology, Western Australian Institute for Medical Research and UWA Centre for Medical Research, University of Western Australia, Perth; Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton; Department of Neurology, Medical University, Sofia; Friedrich-Baur-Institute, Department of Neurology, and Gene Center, Ludwig-Maximilians-University, Munich; Laboratory of Molecular Genetics, National Medical Center, Institute of Hematology and Immunology, Department of Molecular Genetics and Diagnostics, National Center for Public Health, National Institute of Environmental Health, and Department of Pediatric Neurology, Bethesda Children’s Hospital, Budapest; Second Department of Biology, Faculty of Humanities and Natural Sciences, University of Presov, Presov, Slovakia; Laboratoire de Biochimie et Genetique Moleculaire, Groupe Hospitalier Cochin, Paris; Neurosciences Group, Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, Oxford; Kanchi Kamakoti Childs Trust Hospital, Chennai, India; Department of Medical Genetics, University of Alberta, Alberta, Canada; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Department of Human and Medical Genetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
| |
Collapse
|
36
|
Hartley A, Glynn SE, Barynin V, Baker PJ, Sedelnikova SE, Verhees C, de Geus D, van der Oost J, Timson DJ, Reece RJ, Rice DW. Substrate specificity and mechanism from the structure of Pyrococcus furiosus galactokinase. J Mol Biol 2004; 337:387-98. [PMID: 15003454 DOI: 10.1016/j.jmb.2004.01.043] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2003] [Revised: 01/16/2004] [Accepted: 01/24/2004] [Indexed: 11/29/2022]
Abstract
Galactokinase (GalK) catalyses the first step of the Leloir pathway of galactose metabolism, the ATP-dependent phosphorylation of galactose to galactose-1-phosphate. In man, defects in galactose metabolism can result in disorders with severe clinical consequences, and deficiencies in galactokinase have been linked with the development of cataracts within the first few months of life. The crystal structure of GalK from Pyrococcus furiosus in complex with MgADP and galactose has been determined to 2.9 A resolution to provide insights into the substrate specificity and catalytic mechanism of the enzyme. The structure consists of two domains with the active site in a cleft at the domain interface. Inspection of the substrate binding pocket identifies the amino acid residues involved in galactose and nucleotide binding and points to both structural and mechanistic similarities with other enzymes of the GHMP kinase superfamily to which GalK belongs. Comparison of the sequence of the Gal3p inducer protein, which is related to GalK and which forms part of the transcriptional activation of the GAL gene cluster in the yeast Saccharomyces cerevisiae, has led to an understanding of the molecular basis of galactose and nucleotide recognition. Finally, the structure has enabled us to further our understanding on the functional consequences of mutations in human GalK which cause galactosemia.
Collapse
Affiliation(s)
- Andrew Hartley
- Krebs Institute, Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield S10 2TN, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Austerlitz F, Kalaydjieva L, Heyer E. Detecting Population Growth, Selection and Inherited Fertility From Haplotypic Data in Humans. Genetics 2003; 165:1579-86. [PMID: 14668404 PMCID: PMC1462861 DOI: 10.1093/genetics/165.3.1579] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
The frequency of a rare mutant allele and the level of allelic association between this allele and one or several closely linked markers are frequently measured in genetic epidemiology. Both quantities are related to the time elapsed since the appearance of the mutation in the population and the intrinsic growth rate of the mutation (which may be different from the average population growth rate). Here, we develop a method that uses these two kinds of genetic data to perform a joint estimation of the age of the mutation and the minimum growth rate that is compatible with its present frequency. In absence of demographic data, it provides a useful estimate of population growth rate. When such data are available, contrasts among estimates from several loci allow demographic processes, affecting all loci similarly, to be distinguished from selection, affecting loci differently. Testing these estimates on populations for which data are available for several disorders shows good congruence with demographic data in some cases whereas in others higher growth rates are obtained, which may be the result of selection or hidden demographic processes.
Collapse
Affiliation(s)
- Frédéric Austerlitz
- Laboratoire Ecologie, Systématique et Evolution, Université Paris-Sud, F-91405 Orsay, France.
| | | | | |
Collapse
|
38
|
Timson DJ, Reece RJ. Functional analysis of disease-causing mutations in human galactokinase. EUROPEAN JOURNAL OF BIOCHEMISTRY 2003; 270:1767-74. [PMID: 12694189 DOI: 10.1046/j.1432-1033.2003.03538.x] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Galactokinase (EC 2.7.1.6) catalyzes the first committed step in the catabolism of galactose. The sugar is phosphorylated at position 1 at the expense of ATP. Lack of fully functional galactokinase is one cause of the inherited disease galactosemia, the main clinical manifestation of which is early onset cataracts. Human galactokinase (GALK1) was expressed in and purified from Escherichia coli. The recombinant enzyme was both soluble and active. Product inhibition studies showed that the most likely kinetic mechanism of the enzyme was an ordered ternary complex one in which ATP is the first substrate to bind. The lack of a solvent kinetic isotope effect suggests that proton transfer is unlikely to be involved in the rate determining step of catalysis. Ten mutations that are known to cause galactosemia were constructed and expressed in E. coli. Of these, five (P28T, V32M, G36R, T288M and A384P) were insoluble following induction and could not be studied further. Four of the remainder (H44Y, R68C, G346S and G349S) were all less active than the wild-type enzyme. One mutant (A198V) had kinetic properties that were essentially wild-type. These results are discussed both in terms of galactokinase structure-function relationships and how these functional changes may relate to the causes of galactosemia.
Collapse
Affiliation(s)
- David J Timson
- School of Biological Sciences, University of Manchester, United Kingdom
| | | |
Collapse
|
39
|
Wise CA, Paris M, Morar B, Wang W, Kalaydjieva L, Bittles AH. A standard protocol for single nucleotide primer extension in the human genome using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2003; 17:1195-1202. [PMID: 12772276 DOI: 10.1002/rcm.1038] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Analysis of single nucleotide polymorphisms (SNPs) has become an increasingly important area of research, with numerous applications in medical genetics, population genetics, forensic science, and agricultural biotechnology. Large-scale SNP analyses require the development of methodologies that are economical, flexible, accurate and capable of automation. Primer extension in conjunction with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOFMS) is currently emerging as a potential method for high-throughput SNP genotyping. We have evaluated a number of published primer extension methods and refined a simple and robust protocol to analyze human autosomal disease-causing mutations and population genetic markers on the Y-chromosome. Twelve different variant sites were examined, and homozygotes, heterozygotes and hemizygotes were accurately typed. A 100% concordance was observed between SNP genotypes obtained using the MALDI-TOFMS technique and alternative genotyping methods, such as restriction fragment length polymorphism (RFLP) assays and denaturing high-performance liquid chromatography (DHPLC). Since multiple polymorphisms can be detected in single reactions, the method provides a cost-effective approach for SNP analysis. The protocol is also extremely flexible (able to accommodate new markers) and can be adapted to a number of platforms without the use of commercial kits.
Collapse
Affiliation(s)
- Cheryl A Wise
- Centre for Human Genetics, Edith Cowan University, Perth, Australia.
| | | | | | | | | | | |
Collapse
|
40
|
Bosch AM, Bakker HD, van Gennip AH, van Kempen JV, Wanders RJA, Wijburg FA. Clinical features of galactokinase deficiency: a review of the literature. J Inherit Metab Dis 2002; 25:629-34. [PMID: 12705493 DOI: 10.1023/a:1022875629436] [Citation(s) in RCA: 112] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Galactokinase deficiency (McKusick 230200) is a rare autosomal recessive inborn error of galactose metabolism. Cataract and, rarely, pseudotumor cerebri caused by galactitol accumulation seem to be the only consistently reported abnormalities in this disorder. We performed a literature search to obtain information on the clinical spectrum of galactokinase deficiency. A total of 25 publications were traced describing 55 galactokinase-deficient patients. Cataract was reported in most patients. Clinical abnormalities other than cataract were reported in 15 (35%) out of 43 cases on which information was available. However, all symptoms were reported infrequently and a causal relationship with the galactokinase deficiency is unlikely. As cataract and pseudotumor cerebri appear to be the sole complications of galactokinase deficiency, the outcome for patients with galactokinase deficiency is much better than for patients with classical galactosaemia (McKusick 230400), a more common autosomal recessive disorder of galactose metabolism caused by galactose-1-phosphate uridyltransferase (GALT; EC 2.7.7.12) deficiency. Long-term follow-up of patients with this disorder has shown that, in spite of a severely galactose-restricted diet, most patients develop abnormalities such as a disturbed mental and/or motor development, dyspraxia and hypergonadotropic hypogonadism. Endogenous production of galactose has been considered an important aetiological factor. Although damage may well occur in utero, available evidence suggests that damage will continue after birth. Inhibition of galactokinase may then be a promising approach for controlling damage in GALT-deficient patients.
Collapse
Affiliation(s)
- A M Bosch
- Emma Children's Hospital, Amsterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|
41
|
Hunter M, Heyer E, Austerlitz F, Angelicheva D, Nedkova V, Briones P, Gata A, de Pablo R, László A, Bosshard N, Gitzelmann R, Tordai A, Kalmar L, Szalai C, Balogh I, Lupu C, Corches A, Popa G, Perez-Lezaun A, Kalaydjieva LV. The P28T mutation in the GALK1 gene accounts for galactokinase deficiency in Roma (Gypsy) patients across Europe. Pediatr Res 2002; 51:602-6. [PMID: 11978884 DOI: 10.1203/00006450-200205000-00010] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Galactokinase deficiency is an inborn error of metabolism that, if untreated, results in the development of cataracts in the first weeks of life. The disorder is rare worldwide, but has a high incidence among the Roma (Gypsies). In 1999, we reported the founder Romani mutation, P28T, identified in affected families from Bulgaria. Subsequent studies have detected the same mutation in Romani patients from different European countries. The screening of 803 unrelated control individuals of Romani ethnicity from Bulgaria, Hungary, and Spain has shown an overall carrier rate of 1:47 and an expected incidence of affected births about 1:10,000. Using disease haplotype analysis, the age of the P28T mutation was estimated at 750 y, preceding the splits of the proto-Roma into the numerous populations resident in Europe today. The findings suggest that the mutation has spread with the early diaspora of the Roma throughout Europe. Superimposed on this old distribution pattern is the new migration wave of the last decade, with large numbers of Roma moving to Western Europe as a result of the economic changes in the East and the wars in former Yugoslavia. The changing demographic pattern of Romani minorities can be expected to lead to a homogenization of the incidence of "private" Romani disorders and founder mutations. The P28T mutation is thus likely to account for a high proportion of galactokinase deficiency cases across Europe. Mutation-based pilot newborn screening programs would provide current incidence figures and help to design long-term prevention of infantile cataracts due to galactokinase deficiency.
Collapse
Affiliation(s)
- Michael Hunter
- Centre for Human Genetics, Edith Cowan University, Perth, W.A., Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Reich S, Hennermann J, Vetter B, Neumann LM, Shin YS, Söling A, Mönch E, Kulozik AE. An unexpectedly high frequency of hypergalactosemia in an immigrant Bosnian population revealed by newborn screening. Pediatr Res 2002; 51:598-601. [PMID: 11978883 DOI: 10.1203/00006450-200205000-00009] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
In galactokinase (GALK) deficiency, galactose cannot be phosphorylated into galactose-1-phosphate, which leads to cataract formation. Neonatal screening for hypergalactosemia in Berlin has been performed by thin-layer chromatography since 1978, which detects classical galactosemia and GALK deficiency. Until 1991, GALK deficiency has not been identified in a total of approximately 260,000 samples. In contrast, from 1992 to 1999, nine patients were detected in a total of approximately 240,000 screened newborns. One Turkish patient was homozygous for two novel S142I/G148C GALK mutations in close proximity to the putative ATP-binding site of the enzyme. The other eight children were born to five families belonging to the Bosnian refugee population consisting of approximately 30,000 individuals who have arrived in Berlin since 1991. In two of these families, GALK deficiency was subsequently diagnosed in siblings who had cataract surgery at 4 and 5 y of age, respectively. In all these 10 Bosnian patients, a homozygous P28T mutation located near the active center of the enzyme was identified. We propose that neonatal screening of populations with a significant proportion of Bosnians and possibly other southeastern Europeans, e.g. Romani, should be particularly directed toward GALK deficiency, an inborn error of metabolism that is readily amenable to effective treatment.
Collapse
Affiliation(s)
- Susanne Reich
- Children's Hospital, Charité, Campus Virchow, Humboldt University, D-10247 Berlin, Germany
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Timson DJ, Reece RJ. Kinetic analysis of yeast galactokinase: implications for transcriptional activation of the GAL genes. Biochimie 2002; 84:265-72. [PMID: 12106903 DOI: 10.1016/s0300-9084(02)01399-8] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Galactokinase (EC 2.7.1.6) catalyses the first step in the catabolism of galactose. Yeast galactokinase, Gal1p, and the closely related but catalytically inactive Gal3p, also function as ligand sensors in the GAL genetic switch. In the presence of galactose and ATP (the substrates of the reaction catalysed by Gal1p) Gal1p or Gal3p can bind to Gal80p, a transcriptional repressor. This relieves the inhibition of a transcriptional activator, Gal4p, and permits expression of the GAL genes. In order to learn more about the mechanism of ligand sensing by Gal3p and Gal1p, we studied the kinetics of the reaction catalysed by Gal1p. Galactose-1-phosphate, a product of the reaction, is a mixed inhibitor both with respect to galactose and to ATP suggesting that the reaction proceeds via a compulsory, ordered, ternary complex mechanism. There is little variation in either the turnover number or the specificity constants in the pH range 6.0-9.5, implying that no catalytic base is required in the reaction. These data are discussed both in the context of galactokinase enzymology and their implications for the mechanism of transcriptional induction.
Collapse
Affiliation(s)
- David J Timson
- School of Biological Sciences, The University of Manchester, 2.205 Stopford Building, Oxford Road, M13 9PT, Manchester, UK
| | | |
Collapse
|
44
|
Kurt I, Serdar M, Mutlu F, Bayer A, Allen JT, Kutluay T. Galactokinase deficiency: a case report. J Pediatr Ophthalmol Strabismus 2002; 39:41-3. [PMID: 11859915 DOI: 10.3928/0191-3913-20020101-09] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- Ismail Kurt
- Department of Clinical Biochemistry, Gulhane Medical School, Ankara, Turkey
| | | | | | | | | | | |
Collapse
|
45
|
Gresham D, Morar B, Underhill PA, Passarino G, Lin AA, Wise C, Angelicheva D, Calafell F, Oefner PJ, Shen P, Tournev I, de Pablo R, Kuĉinskas V, Perez-Lezaun A, Marushiakova E, Popov V, Kalaydjieva L. Origins and divergence of the Roma (gypsies). Am J Hum Genet 2001; 69:1314-31. [PMID: 11704928 PMCID: PMC1235543 DOI: 10.1086/324681] [Citation(s) in RCA: 165] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2001] [Accepted: 10/01/2001] [Indexed: 11/03/2022] Open
Abstract
The identification of a growing number of novel Mendelian disorders and private mutations in the Roma (Gypsies) points to their unique genetic heritage. Linguistic evidence suggests that they are of diverse Indian origins. Their social structure within Europe resembles that of the jatis of India, where the endogamous group, often defined by profession, is the primary unit. Genetic studies have reported dramatic differences in the frequencies of mutations and neutral polymorphisms in different Romani populations. However, these studies have not resolved ambiguities regarding the origins and relatedness of Romani populations. In this study, we examine the genetic structure of 14 well-defined Romani populations. Y-chromosome and mtDNA markers of different mutability were analyzed in a total of 275 individuals. Asian Y-chromosome haplogroup VI-68, defined by a mutation at the M82 locus, was present in all 14 populations and accounted for 44.8% of Romani Y chromosomes. Asian mtDNA-haplogroup M was also identified in all Romani populations and accounted for 26.5% of female lineages in the sample. Limited diversity within these two haplogroups, measured by the variation at eight short-tandem-repeat loci for the Y chromosome, and sequencing of the HVS1 for the mtDNA are consistent with a small group of founders splitting from a single ethnic population in the Indian subcontinent. Principal-components analysis and analysis of molecular variance indicate that genetic structure in extant endogamous Romani populations has been shaped by genetic drift and differential admixture and correlates with the migrational history of the Roma in Europe. By contrast, social organization and professional group divisions appear to be the product of a more recent restitution of the caste system of India.
Collapse
Affiliation(s)
- David Gresham
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Bharti Morar
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Peter A. Underhill
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Giuseppe Passarino
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Alice A. Lin
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Cheryl Wise
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Dora Angelicheva
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Francesc Calafell
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Peter J. Oefner
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Peidong Shen
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Ivailo Tournev
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Rosario de Pablo
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Vaidutis Kuĉinskas
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Anna Perez-Lezaun
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Elena Marushiakova
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Vesselin Popov
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| | - Luba Kalaydjieva
- Centre for Human Genetics, Edith Cowan University, and Western Australian Institute for Medical Research, Perth; Department of Genetics, Stanford University School of Medicine, Stanford, CA; Dipartimento di Biologia Cellulare, Università della Calabria, Rende, Italy; Unitat de Biologia Evolutiva, Facultat de Ciencies i de la Vida, Universitat Pompeu Fabra, Barcelona; Stanford Genome Technology Center, Palo Alto, CA; Department of Neurology, Medical University, and Foundation for Health Problems of Ethnic Minorities, and Institute of Ethnology, Bulgarian Academy of Sciences, Sofia; Unidad de Immunologia, Clinica Puerta de Hierro, Madrid; and Human Genetics Centre, Medical Faculty, University of Vilnius, Vilnius, Lithuania
| |
Collapse
|
46
|
Kalaydjieva L, Gresham D, Calafell F. Genetic studies of the Roma (Gypsies): a review. BMC MEDICAL GENETICS 2001; 2:5. [PMID: 11299048 PMCID: PMC31389 DOI: 10.1186/1471-2350-2-5] [Citation(s) in RCA: 106] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/15/2001] [Accepted: 04/02/2001] [Indexed: 11/10/2022]
Abstract
BACKGROUND Data provided by the social sciences as well as genetic research suggest that the 8-10 million Roma (Gypsies) who live in Europe today are best described as a conglomerate of genetically isolated founder populations. The relationship between the traditional social structure observed by the Roma, where the Group is the primary unit, and the boundaries, demographic history and biological relatedness of the diverse founder populations appears complex and has not been addressed by population genetic studies. RESULTS Recent medical genetic research has identified a number of novel, or previously known but rare conditions, caused by private founder mutations. A summary of the findings, provided in this review, should assist diagnosis and counselling in affected families, and promote future collaborative research. The available incomplete epidemiological data suggest a non-random distribution of disease-causing mutations among Romani groups. CONCLUSION Although far from systematic, the published information indicates that medical genetics has an important role to play in improving the health of this underprivileged and forgotten people of Europe. Reported carrier rates for some Mendelian disorders are in the range of 5-15%, sufficient to justify newborn screening and early treatment, or community-based education and carrier testing programs for disorders where no therapy is currently available. To be most productive, future studies of the epidemiology of single gene disorders should take social organisation and cultural anthropology into consideration, thus allowing the targeting of public health programs and contributing to the understanding of population structure and demographic history of the Roma.
Collapse
Affiliation(s)
- Luba Kalaydjieva
- Centre for Human Genetics, Edith Cowan University, Perth, Australia
- Western Australian Institute for Medical Research, Perth, Australia
| | - David Gresham
- Centre for Human Genetics, Edith Cowan University, Perth, Australia
| | - Francesc Calafell
- Unitat de Biologia Evolutiva, Facultat de Ciencies de la Salut i de la Vida, Universitat Pompeu Fabra, Barcelona, Spain
| |
Collapse
|
47
|
Okano Y, Asada M, Fujimoto A, Ohtake A, Murayama K, Hsiao KJ, Choeh K, Yang Y, Cao Q, Reichardt JK, Niihira S, Imamura T, Yamano T. A genetic factor for age-related cataract: identification and characterization of a novel galactokinase variant, "Osaka," in Asians. Am J Hum Genet 2001; 68:1036-42. [PMID: 11231902 PMCID: PMC1275622 DOI: 10.1086/319512] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2000] [Accepted: 01/26/2001] [Indexed: 11/03/2022] Open
Abstract
Galactokinase (GALK) deficiency is an autosomal recessive disorder characterized by hypergalactosemia and cataract formation. Through mass screening of newborn infants, we identified a novel and prevalent GALK variant (designated here as the "Osaka" variant) associated with an A198V mutation in three infants with mild GALK deficiency. GALK activity and the amount of immunoreactive protein in the mutant were both 20% of normal construct in expression analysis. The K(m) values for galactose and ATP-Mg(2+) in erythrocytes with homozygous A198V were similar to those of the healthy adult control subjects. A population study for A198V revealed prevalences of 4.1% in Japanese and 2.8% in Koreans, lower incidence in Taiwanese and Chinese, no incidence in blacks and whites from the United States, and a significantly high frequency (7.8%; P < .023) in Japanese individuals with bilateral cataract. This variant probably originated in Japanese and Korean ancestors and is one of the genetic factors that causes cataract in elderly individuals.
Collapse
Affiliation(s)
- Y Okano
- Department of Pediatrics, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Novelli G, Reichardt JK. Molecular basis of disorders of human galactose metabolism: past, present, and future. Mol Genet Metab 2000; 71:62-5. [PMID: 11001796 DOI: 10.1006/mgme.2000.3073] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Molecular cloning and characterization of all three human galactose-metabolic genes have led to the identification of a number of mutations which result in three forms of galactosemia which are caused by kinase (GALK), transferase (GALT), or epimerase (GALE) deficiency. We review here recent developments in the molecular characterization of all three disorders of human galactose metabolism. Recent progress in the biochemical and/or structural analyses of the GALT and GALE proteins has complemented human mutational studies. Interestingly, genotype/phenotype correlations have been modest as in some other Mendelian disorders. We discuss possible reasons for this apparent paradox. Finally, we note the panethnic nature of galactosemia and suggest a hypothesis for it.
Collapse
Affiliation(s)
- G Novelli
- Dipartimento di Biopatologia e Diagnostica per Immagini, Università di Roma Tor Vergata, Rome, 00133, Italy
| | | |
Collapse
|
49
|
Murthy TV, Jayadeva Bhat P. Disruption of galactokinase signature sequence in gal3p of Saccharomyces cerevisiae does not lead to loss of signal transduction function. Biochem Biophys Res Commun 2000; 273:824-8. [PMID: 10891331 DOI: 10.1006/bbrc.2000.3015] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Gal3p of Saccharomyces cerevisiae is a 520-amino-acid residue protein, which activates the GAL genes in the presence of galactose by relieving the repression of Gal80p. It shows significant amino acid sequence homology to galactokinases but does not possess galactokinase activity. Deletion mutants of Gal3p were generated to identify the role of N-terminal amino acid residues required for function. The mutant versions of Gal3p could be detected on a Western blot. The Gal3p mutant lacking N-terminal 50-amino-acid residues which is disrupted for galactokinase signature sequence was found to be functional. These results suggest that the evolutionarily conserved galactokinase signature sequence present in known galactokinases may not have a role in Gal3p function.
Collapse
Affiliation(s)
- T V Murthy
- Molecular Genetics Laboratory, Indian Institute of Technology, Powai, Mumbai, 400 076, India
| | | |
Collapse
|
50
|
Kolosha V, Anoia E, de Cespedes C, Gitzelmann R, Shih L, Casco T, Saborio M, Trejos R, Buist N, Tedesco T, Skach W, Mitelmann O, Ledee D, Huang K, Stambolian D. Novel mutations in 13 probands with galactokinase deficiency. Hum Mutat 2000; 15:447-53. [PMID: 10790206 DOI: 10.1002/(sici)1098-1004(200005)15:5<447::aid-humu6>3.0.co;2-m] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Galactokinase is an essential enzyme in the metabolism of galactose. Patients with deficiencies in galactokinase exhibit early-onset cataracts. We examined the sequence of the human galactokinase gene (GK1) from 13 patients exhibiting galactokinase deficiency and identified 12 novel mutations. One of the mutations occurred in six of the 13 probands examined, and the remaining 11 were unique mutations. Expression of each of the mutant GK1 genes in Xenopus oocytes resulted in very low galactokinase activity levels. These results provide important information regarding the types of GK1 mutations that occur in the human population.
Collapse
Affiliation(s)
- V Kolosha
- Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|